Measuring and Valuing Outcomes
We have established an excellent reputation for leading innovative, ideas-driven, and theoretically sound research on the measurement and valuation of outcomes. Health care systems should put patient-relevant outcomes at the heart of decisions about funding and providing health and social care.
Patient preferences for treatment in relapsed/refractory acute leukemia
23 October 2025
When acute leukemia relapses, treatment decisions can be complex. Patients may face trade-offs between survival benefits, side effects and how treatment is delivered. This study asked people with acute leukemia across five countries what matters most to them when making these choices.
Understanding the preferences of people with acute leukemia for different health outcomes
25 September 2025
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe the problems they have with different aspects of their health. In this study, we wanted to understand which aspects, or “dimensions”, of health-related quality-of-life are most important to the general public and to persons with acute leukemia.
OHE submission to the UK Parliamentary Inquiry on an Ageing Society
20 May 2025
OHE’s written submission to parliament focused on raising population health in older age and increasing access to fertility treatments as two possible avenues to address the challenges of demographic change.
GLP-1 Receptor Agonists: Shifting Obesity Management
12 May 2025
The glucagon-like peptide-1 (GLP-1) receptor agonist market is experiencing rapid growth, with more than 150 drug candidates currently in development as reported by Research & Markets,…
Adding a “Cognition Bolt-on” to EQ-5D-5L: Insights from New Research and What’s Next
10 April 2025
As part of EuroQol’s current priority-setting work, the development of bolt-ons for the EQ-5D-5L instrument has taken centre stage. A “bolt-on toolbox” is being developed to…
EQ-5D and beyond: OHE’s contributions to EuroQol research and meetings
27 February 2025
Measuring and valuing health outcomes is arguably what makes health economics such a unique and sometimes controversial discipline. The idea of putting a numerical value on…
Understanding societal preferences for priority by disease severity in England & Wales
14 November 2024
How does NICE’s severity modifier work? NICE implemented a new severity modifier in February 2022 as part of a wider update to its methods. Its aim…
The Price of Success: Can innovative payment models support access to combination therapies in Europe?
12 November 2024
This panel considered the arguments for and against a system of differential pricing for combination therapies in Europe. They debated whether approaches to pricing in Europe…
Kahneman’s legacy in health economics
4 April 2024
Daniel Kahneman (1934 – 2024) was a Nobel Prize-winning psychologist known for his pioneering work in behavioural economics.